Sweden-based immunotherapy startup BioArctic adds AbbVie to its growing list of partner teams, in an effort to find an effective treatment of Parkinson's Disease
AbbVie partners with Karolinska immunotherapy startup in Parkinson's
Swedish startup BioArctic has added AbbVie ($ABBV) to a partnership roster that already includes another major biopharma, Eisai. The new deal is slated to develop and commercialize the startup's antibody portfolio against the protein alpha-synuclein to treat Parkinson's disease and other potential indications.
Join in on the conversation with Simon when you subscribe to Better Business Development.